News & Analysis on Clinical Trial Services & Contract Research And Development
CORRECTION
Hundreds of workers brought in to help fix manufacturing issues at a Boehringer Ingelheim facility will not be affected despite the firm looking to shave 600 jobs in a €450m ($580m) cost-cutting initiative.
The market opportunity for each Indian drugmakers granted a license to manufacture Gilead’s hepatitis C drug Sovaldi could be worth over $600m, an analyst has calculated.
More commentary on the US FDA’s informed consent draft guidance is trickling out, this time with ACRO (Association of Clinical Research Organizations) and the Dana Farber Cancer Institute offering their take on what should be included in the final guidance.
As the US Drug Supply Chain Security Act (DSCSA) traceability requirements become mandatory in 2015, standards group GS1 is offering a 137-page guideline to help manufacturers follow the new stipulations.
The Pharma industry has responded to the Ebola crisis in West Africa with developmental vaccines and aid donations, but drugmakers still need to be incentivised to develop new therapies according to the WHO.
Newly public Horizon Discovery Group says it is looking for more acquisitions to become a fully integrated products, services and research provider as revenues soars 35%.
Life science sector consolidation is a concern for some biomanufacturers, who say mega mergers like Merck KGaA’s $17bn acquisition of Sigma-Aldrich will limit their ability to negotiate on prices.